For research use only. Not for therapeutic Use.
TYA-018 is an orally active, potent and highly selective HDAC6 inhibitor. TYA-018 can protect heart function in mice. TYA-018 also enhances energetics in mice by increasing expression of targets associated with fatty acid metabolism, protein metabolism, and oxidative phosphorylation[1].
TYA-018 (15 mg/kg, Oral gavage, daily, for 8 weeks) protects against sarcomere damage and reduced Nppb expression in BAG3cKO mice[1].
| Catalog Number | I041277 |
| CAS Number | 2653254-31-8 |
| Synonyms | N-(3-chlorophenyl)-N-[[5-[5-(difluoromethyl)-1,3,4-oxadiazol-2-yl]-1,3-thiazol-2-yl]methyl]ethanesulfonamide |
| Molecular Formula | C15H13ClF2N4O3S2 |
| Purity | ≥95% |
| InChI | InChI=1S/C15H13ClF2N4O3S2/c1-2-27(23,24)22(10-5-3-4-9(16)6-10)8-12-19-7-11(26-12)14-20-21-15(25-14)13(17)18/h3-7,13H,2,8H2,1H3 |
| InChIKey | DAMJZODYLBMFHQ-UHFFFAOYSA-N |
| SMILES | CCS(=O)(=O)N(CC1=NC=C(S1)C2=NN=C(O2)C(F)F)C3=CC(=CC=C3)Cl |
| Reference | [1]. Yang J, et al. Phenotypic screening with deep learning identifies HDAC6 inhibitors as cardioprotective in a BAG3 mouse model of dilated cardiomyopathy. Sci Transl Med. 2022 Jul 6;14(652):eabl5654. |
